A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy
暂无分享,去创建一个
S. Colan | M. Lafreniere-Roula | R. Weintraub | A. Pereira | I. Olivotto | S. Mital | M. Russell | L. Benson | C. Semsarian | J. Ingles | C. Manlhiot | S. Wittekind | J. Jefferies | P. Kantor | Carolyn Y. Ho | J. Rossano | C. Villa | B. Kaufman | J. Conway | A. Lal | M. Michels | H. Henderson | R. Butts | J. Mathew | M. Richmond | A. Dragulescu | E. Stephenson | A. Jeewa | S. Balaji | A. Miron | S. Nakano | K. Armstrong | J. Parent | T. Howard | E. Jean-St-Michel | J. Godown | L. Gardin | Chun-Po Steve Fan | P. Aziz | R. Whitehill | Virginie Beauséjour Ladouceur | Tanya Papaz | Stephanie J. Nakano | Taylor S Howard | Taylor S. Howard
[1] N. Sreeram,et al. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study. , 2019, Heart rhythm.
[2] B. Maron,et al. Increasing evidence that risk scores underperform in predicting sudden death in hypertrophic cardiomyopathy , 2019, Heart.
[3] R. Weintraub,et al. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). , 2019, JAMA cardiology.
[4] M. Link,et al. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. , 2019, JAMA cardiology.
[5] B. Maron,et al. The ESC Risk Score is Less Reliable than ACC/AHA Risk Factors in Hypertrophic Cardiomyopathy: When Sensitivity Trumps Specificity. , 2019, The Canadian journal of cardiology.
[6] M. Schaufelberger,et al. Factors influencing long-term heart failure mortality in patients with obstructive hypertrophic cardiomyopathy in Western Sweden: probable dose-related protection from beta-blocker therapy , 2019, Open Heart.
[7] R. Omar,et al. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[8] D. Albuquerque,et al. Role of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Systematic Review and Updated Meta-Analysis of Risk Markers for Sudden Death , 2019, Arquivos brasileiros de cardiologia.
[9] S. Iwai. Sudden Cardiac Death Risk Stratification and the Role of the Implantable Cardiac Defibrillator. , 2019, Cardiology clinics.
[10] C. Autore,et al. Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis , 2018, Heart.
[11] T. Paul,et al. Transvenous and non-transvenous implantable cardioverter-defibrillators in children, adolescents, and adults with congenital heart disease: who is at risk for appropriate and inappropriate shocks? , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[12] E. Ashley,et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.
[13] S. Colan,et al. Long-Term Outcomes of Hypertrophic Cardiomyopathy Diagnosed During Childhood: Results From a National Population-Based Study , 2018, Circulation.
[14] C. Rapezzi,et al. Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events , 2018, JAMA cardiology.
[15] Shaji C Menon,et al. Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap? , 2018, Progress in pediatric cardiology.
[16] G. Boriani,et al. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators , 2018, Circulation. Arrhythmia and electrophysiology.
[17] N. Peters,et al. Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy , 2018, The American journal of cardiology.
[18] M. Lafreniere-Roula,et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy , 2018, Clinical genetics.
[19] V. Vassiliou,et al. Hypertrophic Cardiomyopathy—Past, Present and Future , 2017, Journal of clinical medicine.
[20] A. Keren,et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) , 2017, Circulation.
[21] Michael A. Burke,et al. Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy. , 2016, Journal of the American College of Cardiology.
[22] S. Mital,et al. Abstract 17056: Validation of the Adult Hypertrophic Cardiomyopathy Sudden Death Risk Calculator in a Pediatric Population , 2016 .
[23] H. Rakowski,et al. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. , 2016, European heart journal.
[24] S. Colan,et al. Structural Measurements and Adjustments for Growth , 2016 .
[25] S. Colan. Normal Echocardiographic Values for Cardiovascular Structures , 2016 .
[26] M. Link,et al. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. , 2015, Journal of the American College of Cardiology.
[27] B. Maron,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.
[28] H. Rehm,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[29] K. Gauvreau,et al. Time Dependence of Risks and Benefits in Pediatric Primary Prevention Implantable Cardioverter-Defibrillator Therapy , 2014, Circulation. Arrhythmia and electrophysiology.
[30] Giuseppe Limongelli,et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.
[31] Thomas A. Gerds,et al. Concordance for prognostic models with competing risks , 2014, Biostatistics.
[32] M. Link,et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.
[33] P. Lambiase,et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy , 2013, Heart.
[34] Stef van Buuren,et al. Imputation in practice , 2012 .
[35] Barry J Maron,et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.
[36] Hein Putter,et al. mstate: An R Package for the Analysis of Competing Risks and Multi-State Models , 2011 .
[37] J. Vogt,et al. Incidence of adequate ICD interventions in patients with hypertrophic cardiomyopathy supposed to be at high risk for sudden cardiac death , 2010, Acta cardiologica.
[38] C. Semsarian,et al. Multiple Mutations in Genetic Cardiovascular Disease: A Marker of Disease Severity? , 2009, Circulation. Cardiovascular genetics.
[39] P. Noseworthy,et al. Genetic Determinants of Sudden Cardiac Death , 2008, Circulation.
[40] P. Elliott,et al. Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic Cardiomyopathy , 2008, Circulation. Cardiovascular genetics.
[41] J. Triedman,et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. , 2008, Journal of the American College of Cardiology.
[42] M. Link,et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.
[43] P. Elliott,et al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy , 2006, Heart.
[45] T. Nealon. The American Association for Thoracic Surgery , 1972 .
[46] B. Knight,et al. ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy. , 2016, Arrhythmia & electrophysiology review.
[47] Deepak L. Bhatt,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[48] D. Knol,et al. Bmc Medical Research Methodology Open Access Variable Selection under Multiple Imputation Using the Bootstrap in a Prognostic Study , 2007 .